Compare Ginkgo Bioworks Holdings Inc (DNA) vs Liberty Global Ltd Class C (LBTYK) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.

The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.

LBTYK trades at $8.75, near its 52-week low, reflecting a bearish technical trend with weak moving averages and oscillators. Fundamentally, the company reported a net loss of -$7.14B in 2025 despite $4.88B in revenue, though 2026 shows improvement with a reduced loss of -$3.0B. Recent strategic moves include the Ziggo Group spin-off preparation and an AI partnership to enhance customer experience.

The stock presents a high-risk opportunity with a discounted valuation (P/S 0.61, P/B 0.32) and strong analyst support (69% buy ratings, $12.67 target). Key risks are persistent losses and execution challenges, but upside potential exists if Ziggo's 2027 listing and cost controls drive profitability.